cjc-1295 ipamorelin pituitary suppression CJC and aren't the same— they target different pathways in the to enhance growth hormone release. Stacked correctly = better results. #growthhormone #peptide #doctor #cjc #ipamorelin CJC-1295 / Ipamorelin Peptide Injections

Drug Target

MBio 6:e00379

Precision Choose Hexarelin When: Cardiac research is the primary focus (unique cardioprotective effects) Maximum acute GH release is needed for short-term studies Cycling protocols are acceptable Hormonal side effects can be monitored and managed Choose Ipamorelin When: Clean GH signal without confounding hormonal effects is essential Long-term or continuous protocols are planned Cortisol and prolactin effects must be avoided Combination with CJC-1295 for synergistic effects Research requires repeatable, consistent GH stimulation Evolution of GHRPs: Hexarelin represents the "first-generation" goal of maximum GH potency

It is crucial to remember that these peptides are not authorized for usage in humans and are only meant for research

Current treatments are largely palliative and do not address the underlying fibrosis